North America Pertussis Vaccination Market size was valued at USD 0.8 Billion in 2022 and is projected to reach USD 1.1 Billion by 2030, growing at a CAGR of 4.0% from 2024 to 2030.
The North America pertussis vaccination market by application is primarily segmented into two categories: infants and adults. Pertussis, commonly known as whooping cough, is a contagious respiratory disease that can be particularly dangerous for infants, often leading to severe complications. The application of pertussis vaccines in infants is a crucial area of focus in the market, as vaccination in this age group is widely recognized as one of the most effective ways to reduce the incidence of whooping cough. The CDC (Centers for Disease Control and Prevention) strongly recommends pertussis vaccination for infants as part of the DTaP (Diphtheria, Tetanus, and Pertussis) vaccine series, which is administered in a series of doses starting at two months of age. This application segment is characterized by high demand due to the vulnerability of infants to the disease and the need for early and robust immunity. Over the years, efforts to improve vaccination coverage in infants have been key in reducing pertussis outbreaks in North America.
In addition to the infant segment, the pertussis vaccination market also includes adults, particularly pregnant women and those in close contact with infants, as part of the Tdap (Tetanus, Diphtheria, and Pertussis) vaccine. Adults, especially older individuals or those with underlying health conditions, are considered to be at risk for contracting and transmitting pertussis to vulnerable populations, making vaccination a vital public health measure. The focus on vaccinating adults in North America has gained momentum, especially for pregnant women, as it has been shown to provide passive immunity to infants through maternal antibodies. The adult application of pertussis vaccines is thus gaining attention in market dynamics, driven by the increasing awareness about its role in preventing disease transmission to infants and boosting overall herd immunity within the population.
12 Months Below
The "12 Months Below" subsegment within the pertussis vaccination market refers specifically to infants aged 12 months or younger. This demographic is the primary focus of the infant pertussis vaccination efforts, as this age group is particularly vulnerable to severe complications of pertussis. Vaccination during the early stages of life is crucial to preventing the onset of the disease, which can cause symptoms such as severe coughing fits, pneumonia, and even death in extreme cases. The DTaP vaccine series is typically administered in multiple doses, starting at two months of age, with follow-up doses given at 4, 6, and 18 months. The high-risk nature of this age group emphasizes the importance of timely vaccination, which has led to significant market growth in the "12 Months Below" subsegment. Public health campaigns and initiatives targeting immunization rates in this group continue to shape the market dynamics, particularly in the U.S. and Canada.
Vaccination in infants aged 12 months below also plays a critical role in curbing the spread of pertussis within communities. Due to the highly contagious nature of the disease, outbreaks can spread rapidly in areas where vaccination coverage is inadequate. Therefore, increasing vaccination rates in this subsegment is a key objective for health organizations in North America. The rising awareness about the importance of infant immunization and the availability of combination vaccines that provide protection against multiple diseases, including pertussis, are expected to drive the growth of this subsegment. Continued research and development efforts focused on improving vaccine formulations for infants, along with public health initiatives, will likely enhance vaccination rates and contribute to a reduction in pertussis-related morbidity and mortality in the coming years.
12 Months Above
The "12 Months Above" subsegment of the pertussis vaccination market includes children over the age of 12 months, who receive booster doses of the DTaP vaccine as part of the routine immunization schedule. After the initial vaccine series administered to infants, children in this age group receive additional boosters to maintain immunity and ensure ongoing protection against pertussis. The Tdap vaccine, which is a combination vaccine that also protects against tetanus and diphtheria, is recommended for adolescents and adults, but it is crucial in this subsegment for those in the early years of childhood. The vaccination regimen for this age group is vital in ensuring long-term immunity and reducing the risk of pertussis outbreaks. The increasing awareness about the importance of continuing vaccination into childhood has driven the growth of this segment in North America, as parents and healthcare professionals alike recognize the role these vaccines play in preventing severe disease.
In the "12 Months Above" subsegment, booster shots are not only important for maintaining individual protection but also for contributing to the overall herd immunity within the population. As pertussis cases continue to be reported in adolescents and adults, there is an increasing emphasis on booster vaccination for children beyond the age of 12 months to enhance the protection offered by the initial vaccine series. This subsegment benefits from educational campaigns targeting parents, pediatricians, and healthcare providers, with the goal of promoting regular vaccinations and boosting awareness about the significance of timely boosters. Moreover, increasing research into vaccine efficacy and potential new vaccine formulations for children is expected to further expand the market in this subsegment in the coming years.
Download In depth Research Report of Pertussis Vaccination Market
The top companies in the Pertussis Vaccination market are leaders in innovation, growth, and operational excellence. These industry giants have built strong reputations by offering cutting-edge products and services, establishing a global presence, and maintaining a competitive edge through strategic investments in technology, research, and development. They excel in delivering high-quality solutions tailored to meet the ever-evolving needs of their customers, often setting industry standards. These companies are recognized for their ability to adapt to market trends, leverage data insights, and cultivate strong customer relationships. Through consistent performance, they have earned a solid market share, positioning themselves as key players in the sector. Moreover, their commitment to sustainability, ethical business practices, and social responsibility further enhances their appeal to investors, consumers, and employees alike. As the market continues to evolve, these top companies are expected to maintain their dominance through continued innovation and expansion into new markets.
Sanofi Pasteur
GSK
Mitsubishi Tanabe Pharma
KM Biologics
Wuhan Institute of Biological Products
Walvax Biotechnology
Chengdu Institute of Biological Products
Minhai Biotechnology
The North American Pertussis Vaccination market is a dynamic and rapidly evolving sector, driven by strong demand, technological advancements, and increasing consumer preferences. The region boasts a well-established infrastructure, making it a key hub for innovation and market growth. The U.S. and Canada lead the market, with major players investing in research, development, and strategic partnerships to stay competitive. Factors such as favorable government policies, growing consumer awareness, and rising disposable incomes contribute to the market's expansion. The region also benefits from a robust supply chain, advanced logistics, and access to cutting-edge technology. However, challenges like market saturation and evolving regulatory frameworks may impact growth. Overall, North America remains a dominant force, offering significant opportunities for companies to innovate and capture market share.
North America (United States, Canada, and Mexico, etc.)
For More Information or Query, Visit @ Pertussis Vaccination Market Size And Forecast 2024-2030
Key market trends in the North America pertussis vaccination market reflect growing awareness of the importance of immunization across all age groups. Increased focus on vaccination of pregnant women to prevent the transmission of pertussis to infants is one of the most significant trends driving market growth. Vaccinating pregnant women with the Tdap vaccine during the third trimester has proven to be highly effective in reducing the incidence of pertussis in newborns, fostering greater market demand for maternal immunization. In addition, the shift towards combination vaccines, which offer protection against multiple diseases, has resulted in more streamlined vaccination schedules, which can contribute to improved adherence rates among both infants and adults. This trend has been complemented by efforts to enhance public health messaging, particularly around the dangers of pertussis for vulnerable populations, such as newborns and older adults. Moreover, the expansion of vaccination programs in both public and private healthcare sectors is further fueling demand for pertussis vaccines in North America.
Investment opportunities in the North America pertussis vaccination market are significant, as there is ongoing innovation in vaccine development and delivery methods. Opportunities exist for companies focused on the development of more effective and longer-lasting vaccines, particularly in combination with other vaccines for cost efficiency. Additionally, the growing focus on global health and the need for vaccination programs that can be administered in remote or underserved areas presents avenues for innovation in vaccine distribution and administration technology. Another area of investment lies in vaccine awareness campaigns, particularly those targeting pregnant women, healthcare providers, and parents, to increase vaccine uptake. With an increasing focus on herd immunity and the importance of vaccination in preventing disease outbreaks, investors and stakeholders in the healthcare industry have significant opportunities to support growth in the pertussis vaccination market in North America.
What is the pertussis vaccine?
The pertussis vaccine protects against whooping cough, a respiratory illness that can be particularly dangerous for infants and young children. It is often administered as part of the DTaP or Tdap vaccine.
How often should the pertussis vaccine be given?
The pertussis vaccine is typically given in a series of shots, starting at two months of age and followed by booster doses in childhood and adulthood as part of the DTaP and Tdap schedules.
Is the pertussis vaccine safe for pregnant women?
Yes, the Tdap vaccine is safe for pregnant women and is recommended during the third trimester to help protect newborns from pertussis.
Why is the pertussis vaccine important for adults?
Adults, especially those in close contact with infants, are encouraged to get the Tdap vaccine to prevent transmission of pertussis to vulnerable populations like newborns.
What are the benefits of combination vaccines like DTaP and Tdap?
Combination vaccines reduce the number of injections required, simplify the vaccination schedule, and help improve vaccine compliance by protecting against multiple diseases with a single shot.